VincentRK: For those of you interested in multiple myeloma, here is a brief state of the science for treatment. 1/ For newly diagnosed patients, triplets, VRd or DRd, are the standard of care. Current RCTs are examining if we can improve outcome using quadruplets. Eg. PERSEUS trial.

by | Jun 12, 2021 | Twitter

For those of you interested in multiple myeloma, here is a brief state of the science for treatment. 1/ For newly diagnosed patients, triplets, VRd or DRd, are the standard of care. Current RCTs are examining if we can improve outcome using quadruplets. Eg. PERSEUS...

MM_Hub: CONGRESS|#EHA2021| Marc S Raab, discussed the impact of cell based immunotherapy on pretreated refractory MM pt. Role of cytokine release syndrome and immune effector cell associated neurologic syndrome was also discussed #mmsm, #myeloma, @UniHeidelberg

by | Jun 12, 2021 | Twitter

CONGRESS|#EHA2021| Marc S Raab, discussed the impact of cell based immunotherapy on pretreated refractory MM pt. Role of cytokine release syndrome and immune effector cell associated neurologic syndrome was also discussed #mmsm, #myeloma, @UniHeidelberg...

MM_Hub: CONGRESS|#EHA2021|Nikhil C Munshi, highlighted various emerging BCMA targeting CART cell therapies in MM e.g. ide-cel, cilta-cel, P-BCMA & ALLO-715. KarMMa study for Ide-cel results were discussed #mmsm, #myeloma, @harvardmed, @DanaFarber

by | Jun 12, 2021 | Twitter

CONGRESS|#EHA2021|Nikhil C Munshi, highlighted various emerging BCMA targeting CART cell therapies in MM e.g. ide-cel, cilta-cel, P-BCMA & ALLO-715. KarMMa study for Ide-cel results were discussed #mmsm, #myeloma, @harvardmed, @DanaFarber...

MM_Hub: CONGRESS|#EHA2021|@ThierryFacon, presented OS rate from Phase 3 MAIA clinical trial for D-Rd vs Rd alone in pts with NDMM who are transplant ineligible. Results indicated 32% reduction in risk of death #mmsm, #myeloma, Lille University Hospital

by | Jun 12, 2021 | Twitter

CONGRESS|#EHA2021|@ThierryFacon, presented OS rate from Phase 3 MAIA clinical trial for D-Rd vs Rd alone in pts with NDMM who are transplant ineligible. Results indicated 32% reduction in risk of death #mmsm, #myeloma, Lille University Hospital...

MM_Hub: CONGRESS|#EHA2021|@Cristin53875581, determined that the addition of QW SEL to the PI carfilzomib (CAR)-dex (XKd) would be an active & tolerable regimen in pts with heavily pre-treated MM. 78% ORR & overall PFS of 23 months were obtained #mmsm, #myeloma, @DukeCancer

by | Jun 12, 2021 | Twitter

CONGRESS|#EHA2021|@Cristin53875581, determined that the addition of QW SEL to the PI carfilzomib (CAR)-dex (XKd) would be an active & tolerable regimen in pts with heavily pre-treated MM. 78% ORR & overall PFS of 23 months were obtained #mmsm, #myeloma,...